This is a public document obtainable from the FDA. It speaks for itself.

2. FDA Warning Letter to Heyltex

Heyl, a pharmaceutical company from Berlin, is the manufacturer of DMPS. Their subsidiary, Heyltex, is located in Dallas, Texas. My understanding is that they originally sponsored Paula Bickle’s “clinical trials”, but later withdrew. The following is a disciplinary letter from the FDA to Heyltex

3. Oregon Board of Medical Examiners

The Oregon Board of Medical Examiners has disciplined Paula Bickle for practicing medicine without a license. This determination was made based upon the affidavits of four physicians, a nurse and a physician’s assistant, all of whom worked with Dr. Bickle at the Cascade Health Group in Portland. (These are public documents, and can be obtained from the Multnomah County authorities in Salem.) She was later disciplined a second time for violating the conditions of the first decree.

While all of the affidavits are disturbing, one in particular is notable. It is from an individual who is a Physician’s Technician and Registered Medical Assistant. This is a portion of her statement:

“Paula secured the position of Principal Investigator for the study and I was contracted to the drug manufacturer, Heyltex as the Safety Monitor. … In July of 1997, I was in Portland and for the first time had the opportunity to observe how Paula Bickle conducted business at Cascade Health Group. Over a 5 day period I observed practices that were totally unacceptable and that were rejected by her medical director at that time.

As a result of my observations, my personal and professional ethics drew me to the conclusion that this study could not go forward with Paula Bickle as Principal Investigator. My primary responsibility as Monitor is to insure that the protocol is followed and that patient safety and good clinical practices are adhered to and followed to the letter and to report infractions when patient safety is disregarded. My report to Heyltex on Paula’s practices and her direct disregard of the protocol and patient safety led to her being dismissed as the Principal Investigator of this project. Through my association with the Bickles it became increasingly clear that they would take a little truth and wrap it around a lot of untruths while making everything sound believable. This became crystal clear to me during the week I spent in the clinic and questioned various practices and attempted to verify information that I had been previously given. I believe a large part of their motivation is financial in nature with little regard to true quality medical care for individuals or research.

Also of great concern to me is that she is not just impacting patient safety in the Portland community. She conducts training seminars for physicians, dentists and paraprofessionals from all over the U.S. and foreign countries. Some of what she teaches and at least one medical treatment included in the training (at the seminars I attended) to professionals is inaccurate and has the potential for harming the patients of these doctors. This would probably never be traced back to her. She is using reputable professional organizations to gain access to these professionals – that is why they believe she is credible – just like I did in the beginning.”

III. Warren Levin, M.D.

Warren Levin, M.D., was listed as one of the physicians participating in Paula Bickle’s clinical trials. He is also an advocate of the use of DMPS for chronic mercury poisoning.

Dr. Levin spoke at a conference I attended. He was advocating the use of DMPS. During the question and answer period, I took the microphone and told Dr. Levin and the audience of my devastating experience with DMPS. He stated to me, and the audience, that he had never heard of such a reaction to DMPS.

Some months later, a patient provided me with a copy of a letter Dr. Levin had written on his behalf several years earlier. This patient had become permanently disabled from a single injection of DMPS, and Dr. Levin had written a letter in support of his request for disability benefits. (Dr. Levin was not the physician who had treated this patient with DMPS.) In that letter, Dr. Levin spoke to the terrible adverse effects suffered by this patient, and with regard to them, coined the term “backfire”.

It is my understanding that the clinical trials of DMPS never got off the ground. Yet Dr. Levin has information on the internet which would imply otherwise.

A January 2001 addendum to his web page states: “I am delighted to report that the FDA, based largely on the results of the above study, has approved DMPS for use as a treatment for the removal of mercury! It can currently be obtained from compounding pharmacists for use by any physician!!”

This statement is untrue. The FDA has NOT approved DMPS. And “the above study” is a fiction. It may be true that physicians can obtain DMPS from compounding pharmacies, but that does not mean that pharmacies are compounding this drug legally, or that physicians are using it legally. They are not.

Dr. Levin’s internet information is both inaccurate and misleading. I have serious concerns that patients may rely on this information in making decisions about the use of this drug.